Skip to main content

Table 2 Follow-up variables; immunosuppression, outcome and cause of graft loss

From: Induction with interleukin-2 antagonist for transplantation of kidneys from older deceased donors: an observational study

  IL-2 plus IL-2 minus P
  (N=149) (N=83)  
Immunosuppression at 10 weeks    
CsA 99 (67%) 60 (77%) ns
Tacrolimus 31 (21%) 10 (13%) ns
mTOR inhibitor 14 (10%) 9 (12%) ns
CsA dose (mg/day) 250.5 ± 73.5 255.4 ± 87.8 ns
CsA C0 concentration 151.4 ± 56.5 183.3 ± 85.6 0.01
Tacrolimus dose (mg/day) 5.65 ± 2.95 8.70 ± 4.64 ns
Tacrolimus concentration 7.3 ± 2.1 9.2 ± 2.3 ns
Prednisolone dose (mg/day) 12,4 ± 5.6 13.6 ± 5.6 ns
MMF (mg/day) 1678.1 ± 402.9 1750.0 ± 619.9 ns
Outcome    
Delayed graft function 53 (36%) 29 (35%) ns
Acute rejection 90 days post transplant 29 (20%) 34 (41%) 0.001
Acute rejection 180 days post transplant 38 (26%) 35 (42%) 0.01
Steroid-resistant rejection (biopsy proven) 5 (3%) 18 (22%) < 0.001
C4D positive biopsy 4 (5%) 4 (3%) ns
Cause of graft loss    
Death with functioning graft 32 (22%) 24 (29%) ns
Primary non-function 0 6 (7%) 0.002
Primary vascular thrombosis 3 (2%) 2 (2%) ns
Rejection 5 (3%) 10 (12%) 0.02
Recurrent primary disease 0 1 (1%) ns
Urological complications 1 (1%) 0 ns
De novo glomerulonephritis 1 (1%) 0 ns
Insufficient graft function 0 2 (2%) ns
Not specified 2 (1%) 2 (2%) ns